COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CMPS Stock Price Chart Interactive Chart >
CMPS Price/Volume Stats
|Current price||$10.24||52-week high||$32.55|
|Prev. close||$10.30||52-week low||$6.54|
|Day high||$10.49||Avg. volume||331,518|
|50-day MA||$10.46||Dividend yield||N/A|
|200-day MA||$12.15||Market Cap||435.99M|
COMPASS Pathways PLC ADR (CMPS) Company Bio
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Most Popular Stories View All
CMPS Latest News Stream
|Loading, please wait...|
CMPS Latest Social Stream
View Full CMPS Social Stream
Latest CMPS News From Around the Web
Below are the latest news stories about COMPASS PATHWAYS PLC that investors may wish to consider to help them evaluate CMPS as an investment opportunity.
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be acc
Berenberg Bank analyst Caroline Palomeque initiated coverage with a Buy rating on COMPASS Pathways (CMPS - Research Report) today and set a price target of $33.00. The company's shares closed last Friday at $9.96.Palomeque covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Denali Therapeutics, and RegenXBio. According to TipRanks, Palomeque has an average return of -14.6% and a 33.03% success rate on recommended stocks. COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $52.33.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $34.79 and a one-year low of $6.54.
The main psychoactive ingredient found in magic mushrooms can significantly reduce symptoms of difficult-to-treat depression, data from the largest clinical trial ever to test the keenly-watched compound has found. The mid-stage study, conducted by the London-based and Nasdaq-listed COMPASS Pathways, involved 233 patients with so-called treatment-resistant depression who have failed to benefit from at least two antidepressants. COMPASS' compound is believed to target the bits of the brain intimately involved with processing emotion, said James Rucker, consultant psychiatrist and senior clinical lecturer at King’s College London, who was involved in the study.
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS)Q3 2022 Earnings CallNov 03, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, ladies and gentlemen.
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Highlights: Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiatedPhase 2b trial data published in The New England Journal of MedicineCash position at 30 September 2022 of $173.1 millionConference call today at 8:00am ET (12:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health
CMPS Price Returns